REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq:CHRS), today announced that effective February 1, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 22,500 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $8.65, the closing trading price on the grant date.
The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
Coherus BioSciences Contact Information:
IR Contact
Marek Ciszewski
Coherus BioSciences, Inc.
IR@coherus.com
Related news for (CHRS)
- Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
- Coherus Divesting UDENYCA Franchise to Intas Pharmaceuticals for up to $558M
- Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
- Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
- Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium